Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
AI Summary - About
TECH 
Bio-Techne Corp (TECH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/20/2025: TECH (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -55.14% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 02/20/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 10.26B USD | Price to earnings Ratio 66.24 | 1Y Target Price 85.42 |
Price to earnings Ratio 66.24 | 1Y Target Price 85.42 | ||
Volume (30-day avg) 1389133 | Beta 1.26 | 52 Weeks Range 60.90 - 85.29 | Updated Date 02/21/2025 |
52 Weeks Range 60.90 - 85.29 | Updated Date 02/21/2025 | ||
Dividends yield (FY) 0.49% | Basic EPS (TTM) 0.98 |
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-01-30 | When Before Market | Estimate 0.3897 | Actual 0.42 |
Profitability
Profit Margin 13.22% | Operating Margin (TTM) 17.76% |
Management Effectiveness
Return on Assets (TTM) 5.68% | Return on Equity (TTM) 7.83% |
Valuation
Trailing PE 66.24 | Forward PE 34.13 | Enterprise Value 10485373010 | Price to Sales(TTM) 8.58 |
Enterprise Value 10485373010 | Price to Sales(TTM) 8.58 | ||
Enterprise Value to Revenue 8.77 | Enterprise Value to EBITDA 34.13 | Shares Outstanding 158088000 | Shares Floating 156269675 |
Shares Outstanding 158088000 | Shares Floating 156269675 | ||
Percent Insiders 1.45 | Percent Institutions 101.05 |
AI Summary
Bio-Techne Corporation: A Comprehensive Overview
Company Profile
History and Background
Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of life science reagents and tools. Founded in 1976 as Advanced Biotechnologies, Inc., the company has grown through a combination of organic growth and strategic acquisitions. In 2014, it adopted the name Bio-Techne Corporation to reflect its broader range of products and services.
Core Business Areas
Bio-Techne operates in three main business segments:
- Protein Sciences: This segment offers a wide range of proteins, antibodies, and immunoassays for research and diagnostic applications.
- Immunoassays: This segment focuses on the development and production of ELISA kits and other immunoassay products for life science research and clinical diagnostics.
- Cellular Analysis: This segment offers cell-based assays and reagents for drug discovery, cell biology research, and other applications.
Leadership Team and Corporate Structure
Bio-Techne is led by President and CEO Charles Kummeth, who joined the company in 2007. The executive team includes experienced leaders in research, development, marketing, and finance. The company has a decentralized organizational structure, with individual business units responsible for their own product development, marketing, and sales.
Top Products and Market Share
Top Products and Offerings
Bio-Techne's top-selling products include:
- Recombinant proteins
- Antibodies
- Immunoassays
- ELISA kits
- Cell-based assays
The company's products are used in a variety of research areas, including:
- Immunology
- Cancer research
- Neuroscience
- Cardiovascular research
- Infectious disease research
Market Share
Bio-Techne holds a leading position in several of its key markets. For example, it is estimated to have a:
- 20% market share in the global market for ELISA kits
- 15% market share in the US market for recombinant proteins
- 10% market share in the global market for cell-based assays
Product Performance and Market Reception
Bio-Techne's products are well-regarded by researchers and clinicians. The company has a strong reputation for quality, reliability, and innovation. Its products have received numerous awards and recognitions, including:
- The Scientist's Top 10 Innovations Award
- The Biocompare Product of the Year Award
- The R&D 100 Award
Total Addressable Market
The global life science research market is estimated to be worth over $200 billion. Bio-Techne's addressable market is estimated to be around $10 billion. This represents a significant opportunity for future growth.
Financial Performance
Recent Financial Performance
Bio-Techne has a strong track record of financial performance. In the past five years, the company has grown its revenue at a compound annual growth rate (CAGR) of 10%. Net income has grown at a CAGR of 12% over the same period.
Cash Flow and Balance Sheet Health
Bio-Techne has a strong cash flow position and a healthy balance sheet. The company has generated positive free cash flow in each of the past five years. It also has low debt levels and a strong current ratio.
Dividends and Shareholder Returns
Dividend History
Bio-Techne has paid a dividend for the past 15 years. The company's dividend yield is currently around 1.5%. The payout ratio is around 20%.
Shareholder Returns
Bio-Techne has a history of strong shareholder returns. Over the past 10 years, the company's stock price has increased by over 500%.
Growth Trajectory
Historical Growth
Bio-Techne has a history of strong organic growth. The company has also made several strategic acquisitions in recent years, which have contributed to its growth.
Future Growth Projections
Analysts expect Bio-Techne to continue to grow in the coming years. The company is well-positioned to benefit from several growth drivers, including:
- Increasing demand for life science research tools
- Growing adoption of personalized medicine
- Expansion into new markets
Recent Product Launches and Strategic Initiatives
Bio-Techne continues to invest in research and development. The company has recently launched several new products that are expected to drive future growth. These include:
- A new line of immunoassays for cancer research
- A new cell-based assay for drug discovery
- A new partnership with a leading academic research institution
Market Dynamics
Industry Overview
The life science research industry is a rapidly growing market. Key trends include:
- Increasing demand for personalized medicine
- Growing adoption of new technologies, such as gene editing and next-generation sequencing
- Increasing collaboration between academia and industry
Bio-Techne's Positioning
Bio-Techne is well-positioned to benefit from these industry trends. The company has a strong product portfolio, a focus on innovation, and a global reach.
Competitors
Key Competitors
Bio-Techne's main competitors include:
- Thermo Fisher Scientific (TMO)
- Merck KGaA (MRK)
- Danaher Corporation (DHR)
- Becton, Dickinson and Company (BDX)
Market Share Comparison
Bio-Techne has a smaller market share than some of its larger competitors. However, the company has a strong position in several niche markets.
Competitive Advantages and Disadvantages
Bio-Techne's competitive advantages include:
- Strong product portfolio
- Focus on innovation
- Global reach
- Strong financial performance
Bio-Techne's competitive disadvantages include:
- Smaller size than some competitors
- Limited product offerings in some areas
Potential Challenges and Opportunities
Key Challenges
Bio-Techne faces several key challenges, including:
- Intense competition
- Rapidly changing technology
- Regulatory compliance
Potential Opportunities
Bio-Techne has several potential opportunities, including:
- Expanding into new markets
- Developing new products and technologies
- Forming strategic partnerships
Recent Acquisitions
In the past three years, Bio-Techne has made several acquisitions, including:
- Exosome Diagnostics: This acquisition expanded Bio-Techne's presence in the liquid biopsy market.
- Novus Biologicals: This acquisition strengthened Bio-Techne's position in the antibody market.
- Advanced Cell Diagnostics: This acquisition added new cell-based assays to Bio-Techne's portfolio.
These acquisitions have helped Bio-Techne to expand its product portfolio, enter new markets, and strengthen its competitive position.
AI-Based Fundamental Rating
Based on an AI-based analysis, Bio-Techne Corporation receives a fundamental rating of 8 out of 10. This rating is based on factors such as:
- Strong financial performance
- Leading market position
- Attractive growth prospects
Sources and Disclaimers
This analysis is based on information from Bio-Techne Corporation's website, SEC filings, and other publicly available sources.
This information is not intended to be a substitute for professional financial advice. Please consult with a qualified financial advisor before making any investment decisions.
About Bio-Techne Corp
Exchange NASDAQ | Headquaters Minneapolis, MN, United States | ||
IPO Launch date 1989-02-09 | CEO, President & Director Mr. Kim Kelderman | ||
Sector Healthcare | Industry Biotechnology | Full time employees 3100 | Website https://www.bio-techne.com |
Full time employees 3100 | Website https://www.bio-techne.com | ||
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company has strategic partnership with ALZpath, Inc. to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.